Indication
In combination with chemotherapy for the treatment of locally recurrent unresectable or metastatic triple negative breast cancer in adults whose tumours express PD-L1 with a CPS ≥ 10 and who have not received prior chemotherapy for metastatic disease
Medicine details
- Medicine name:
- pembrolizumab (Keytruda)
- SMC ID:
- SMC2460
- Pharmaceutical company
- Merck Sharp & Dohme Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- 10 October 2022
- SMC meeting date:
- 06 September 2022
- Patient group submission deadline:
- 06 June 2022